{"pmid":32319439,"title":"[CoViD-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.]","text":["[CoViD-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.]","Chronicity and comorbidity influence the risk of CoViD-19 infection and the course of the disease. Epidemiological data and studies performed show different rates of chronic diseases and multimorbidity among patients affected by CoViD-19 in the various countries and areas, but they consistently stress their impact on CoViD-19 infection. In order to protect chronic and frail patients, the Italian Medicines Agency has taken measures to extend the therapeutic plans and monitoring registers; hopefully, therapeutic plans for antidiabetics, drugs for respiratory diseases and oral anticoagulant drugs will be abolished since they do not offer any additional advantage in terms of appropriateness and traceability of outcomes. The MaCroScopio project (Observatory on Chronic Diseases), regarding the CoViD-19 emergency, has started a new research path to foster the integration of the administrative data flows with the CoViD-19 Registers for planning and research purposes in the context of chronicity, as well as to evaluate the economic and organizational impact of the pandemic.","Recenti Prog Med","Martini, Nello","Piccinni, Carlo","Pedrini, Antonella","Maggioni, Aldo","32319439"],"abstract":["Chronicity and comorbidity influence the risk of CoViD-19 infection and the course of the disease. Epidemiological data and studies performed show different rates of chronic diseases and multimorbidity among patients affected by CoViD-19 in the various countries and areas, but they consistently stress their impact on CoViD-19 infection. In order to protect chronic and frail patients, the Italian Medicines Agency has taken measures to extend the therapeutic plans and monitoring registers; hopefully, therapeutic plans for antidiabetics, drugs for respiratory diseases and oral anticoagulant drugs will be abolished since they do not offer any additional advantage in terms of appropriateness and traceability of outcomes. The MaCroScopio project (Observatory on Chronic Diseases), regarding the CoViD-19 emergency, has started a new research path to foster the integration of the administrative data flows with the CoViD-19 Registers for planning and research purposes in the context of chronicity, as well as to evaluate the economic and organizational impact of the pandemic."],"journal":"Recenti Prog Med","authors":["Martini, Nello","Piccinni, Carlo","Pedrini, Antonella","Maggioni, Aldo"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319439","week":"202017|Apr 20 - Apr 26","doi":"10.1701/3347.33180","source":"PubMed","weight":0,"_version_":1664815087816278016,"score":8.518259,"similar":[{"pmid":32333929,"title":"Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic.","text":["Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic.","The 2019 coronavirus disease (COVID-19) pandemic caused by the SARS-CoV-2 virus has affected virtually all aspects of patient care. Healthcare systems around the world are trying to simultaneously treat patients with COVID-19 infection, prepare for its long-term impacts, and manage patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.","Chest","Wong, Alyson W","Fidler, Lee","Marcoux, Veronica","Johannson, Kerri A","Assayag, Deborah","Fisher, Jolene H","Hambly, Nathan","Kolb, Martin","Morisset, Julie","Shapera, Shane","Ryerson, Christopher J","32333929"],"abstract":["The 2019 coronavirus disease (COVID-19) pandemic caused by the SARS-CoV-2 virus has affected virtually all aspects of patient care. Healthcare systems around the world are trying to simultaneously treat patients with COVID-19 infection, prepare for its long-term impacts, and manage patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks."],"journal":"Chest","authors":["Wong, Alyson W","Fidler, Lee","Marcoux, Veronica","Johannson, Kerri A","Assayag, Deborah","Fisher, Jolene H","Hambly, Nathan","Kolb, Martin","Morisset, Julie","Shapera, Shane","Ryerson, Christopher J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333929","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.chest.2020.04.019","keywords":["coronavirus","diagnosis","interstitial lung disease","treatment"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1665071049694248960,"score":188.82721},{"pmid":32305075,"pmcid":"PMC7162648","title":"Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.","text":["Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.","The coronavirus disease 2019 (COVID-19) pandemic is changing the management of many chronic diseases, including that of patients with inflammatory bowel diseases (IBD). In particular, the performance of routine endoscopy is temporarily suspended, and only emergency endoscopy is allowed in many countries where severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread. We highlight different scenarios in which endoscopy should still be performed urgently in patients with IBD, as well as recommendations regarding the use of personal protective equipment. We suggest a pathway for performing safe endoscopy and discuss the potential risks of postponing endoscopy in IBD. Finally, we propose a post-pandemic plan for access to endoscopy.","Lancet Gastroenterol Hepatol","Iacucci, Marietta","Cannatelli, Rosanna","Labarile, Nunzia","Mao, Ren","Panaccione, Remo","Danese, Silvio","Kochhar, Gursimran S","Ghosh, Subrata","Shen, Bo","32305075"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic is changing the management of many chronic diseases, including that of patients with inflammatory bowel diseases (IBD). In particular, the performance of routine endoscopy is temporarily suspended, and only emergency endoscopy is allowed in many countries where severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread. We highlight different scenarios in which endoscopy should still be performed urgently in patients with IBD, as well as recommendations regarding the use of personal protective equipment. We suggest a pathway for performing safe endoscopy and discuss the potential risks of postponing endoscopy in IBD. Finally, we propose a post-pandemic plan for access to endoscopy."],"journal":"Lancet Gastroenterol Hepatol","authors":["Iacucci, Marietta","Cannatelli, Rosanna","Labarile, Nunzia","Mao, Ren","Panaccione, Remo","Danese, Silvio","Kochhar, Gursimran S","Ghosh, Subrata","Shen, Bo"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305075","week":"202017|Apr 20 - Apr 26","doi":"10.1016/S2468-1253(20)30119-9","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664641855710560257,"score":186.72453},{"pmid":32289115,"pmcid":"PMC7128473","title":"Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.","text":["Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.","The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.","JHEP Rep","Boettler, Tobias","Newsome, Philip N","Mondelli, Mario U","Maticic, Mojca","Cordero, Elisa","Cornberg, Markus","Berg, Thomas","32289115"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention."],"journal":"JHEP Rep","authors":["Boettler, Tobias","Newsome, Philip N","Mondelli, Mario U","Maticic, Mojca","Cordero, Elisa","Cornberg, Markus","Berg, Thomas"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289115","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhepr.2020.100113","keywords":["ace-i, angiotensin-converting enzyme inhibitor","ace2, angiotensin-converting enzyme 2","aclf, acute-on-chronic liver failure","alt, alanine aminotransferase","ast, aspartate aminotransferase","covid-19, coronavirus disease 2019","egd, esophagogastroduodenoscopy","erc, endoscopic retrograde cholangiography","hcc, hepatocellular carcinoma","meld, model for end-stage liver disease","nafld, non-alcoholic fatty liver disease","nash, non-alcoholic steatohepatitis","nuc, nucleoside analogue","pis, protease inhibitors","rdrp, rna-dependent rna polymerase","sars-cov-2, severe acute respiratory syndrome coronavirus 2","uln, upper limit of normal"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636391708950528,"score":184.72476},{"pmid":32319129,"title":"Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.","text":["Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.","While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and health care providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, bronchodilators increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.","Pediatr Allergy Immunol","Brough, Helen A","Kalayci, Omer","Sediva, Anna","Untersmayr, Eva","Munblit, Daniel","Rodriquez Del Rio, Pablo","Vazquez-Ortiz, Marta","Arasi, Stefania","Alvaro-Lozano, Montserrat","Tsabouri, Sophia","Galli, Elena","Beken, Burcin","Eigenmann, Philippe A","32319129"],"abstract":["While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and health care providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, bronchodilators increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence."],"journal":"Pediatr Allergy Immunol","authors":["Brough, Helen A","Kalayci, Omer","Sediva, Anna","Untersmayr, Eva","Munblit, Daniel","Rodriquez Del Rio, Pablo","Vazquez-Ortiz, Marta","Arasi, Stefania","Alvaro-Lozano, Montserrat","Tsabouri, Sophia","Galli, Elena","Beken, Burcin","Eigenmann, Philippe A"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319129","week":"202017|Apr 20 - Apr 26","doi":"10.1111/pai.13262","keywords":["covid-19","sars-cov-2","allergy","asthma","biologics","children","coronavirus","corticosteroids","immunodeficiency","treatment"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Optimal"],"_version_":1664815087837249536,"score":179.97481},{"pmid":32307319,"title":"Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries.","text":["Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries.","The current coronavirus disease 2019 (COVID-19) pandemic is placing a huge strain on health systems worldwide. Suggested solutions like social distancing and lockdowns in some areas to help contain the spread of the virus may affect special patient populations like those with chronic illnesses who are unable to access healthcare facilities for their routine care and medicines management. Retail pharmacy outlets are the likely facilities for easy access by these patients. The contribution of community pharmacists in these facilities to manage chronic conditions and promote medication adherence during this COVID-19 pandemic will be essential in easing the burden on already strained health systems. This paper highlights the pharmaceutical care practices of community pharmacists for patients with chronic diseases during this pandemic. This would provide support for the call by the WHO to maintain essential services during the pandemic, in order to prevent non-COVID disease burden on healthcare systems particularly in low-and middle-income countries.","Res Social Adm Pharm","Kretchy, Irene A","Asiedu-Danso, Michelle","Kretchy, James-Paul","32307319"],"abstract":["The current coronavirus disease 2019 (COVID-19) pandemic is placing a huge strain on health systems worldwide. Suggested solutions like social distancing and lockdowns in some areas to help contain the spread of the virus may affect special patient populations like those with chronic illnesses who are unable to access healthcare facilities for their routine care and medicines management. Retail pharmacy outlets are the likely facilities for easy access by these patients. The contribution of community pharmacists in these facilities to manage chronic conditions and promote medication adherence during this COVID-19 pandemic will be essential in easing the burden on already strained health systems. This paper highlights the pharmaceutical care practices of community pharmacists for patients with chronic diseases during this pandemic. This would provide support for the call by the WHO to maintain essential services during the pandemic, in order to prevent non-COVID disease burden on healthcare systems particularly in low-and middle-income countries."],"journal":"Res Social Adm Pharm","authors":["Kretchy, Irene A","Asiedu-Danso, Michelle","Kretchy, James-Paul"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307319","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.sapharm.2020.04.007","keywords":["covid-19","chronic diseases","community pharmacists","lmics","medication adherence","pharmaceutical care"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664632501487796226,"score":179.49442}]}